Molecular Oncology : Impact Factor & More
eISSN: 1878-0261pISSN: 1574-7891
Open AccessShare this on:
Key Metrics
CiteScore 
10.4
Eigenfactor
0.01 - 0.05
H-Index
105
Impact Factor
5 - 10
SJR
Q1Genetics
SNIP
1.38
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Molecular Oncology
Molecular Oncology Journal Specifications
| Overview | |
| Publisher | WILEY |
| Language | English |
| Frequency | Monthly |
| Article Processing Charges | USD 3600 |
| Publication Time | 10 |
| Editorial Review Process | Open peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Federation of European Biochemical Societies |
| Frequency | Monthly |
| Publication Start Year | 2007 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY |
| OA statement | Visit website |
View less
Planning to publish in Molecular Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Molecular Oncology
Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation.
- 30 Jun 2026
- Molecular oncology
In vitro and in silico modelling of ROS1-positive non-small cell lung cancer reveals fusion-dependent tyrosine kinase inhibitor responses.
- 23 Jun 2026
- Molecular oncology
The role of miR-335-5p in the redifferentiation of BRAF p.V600E thyroid cancers.
- 22 Jun 2026
- Molecular oncology
EXPRESSION OF CONCERN: A Newly Identified 45-kDa JAK2 Variant with an Altered Kinase Domain Structure Represents a Novel Mode of JAK2 Kinase Inhibitor Resistance.
- 21 Jun 2026
- Molecular oncology
ZW4864-mediated inhibition of the β-catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer.
- 18 Jun 2026
- Molecular oncology
Liquid biopsy-based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis.
- 16 Jun 2026
- Molecular oncology
Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation.
- 30 Jun 2026
- Molecular oncology
In vitro and in silico modelling of ROS1-positive non-small cell lung cancer reveals fusion-dependent tyrosine kinase inhibitor responses.
- 23 Jun 2026
- Molecular oncology
The role of miR-335-5p in the redifferentiation of BRAF p.V600E thyroid cancers.
- 22 Jun 2026
- Molecular oncology
EXPRESSION OF CONCERN: A Newly Identified 45-kDa JAK2 Variant with an Altered Kinase Domain Structure Represents a Novel Mode of JAK2 Kinase Inhibitor Resistance.
- 21 Jun 2026
- Molecular oncology
ZW4864-mediated inhibition of the β-catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer.
- 18 Jun 2026
- Molecular oncology
Liquid biopsy-based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis.
- 16 Jun 2026
- Molecular oncology
FAQs on Molecular Oncology
How long has Molecular Oncology been actively publishing? 
What is the publishing frequency of Molecular Oncology?
How many articles did Molecular Oncology publish last year?
What is the eISSN & pISSN for Molecular Oncology?
What is Citescore for Molecular Oncology?
What is the H Index for Molecular Oncology ?
What is SNIP score for Molecular Oncology?
What is the SJR for Molecular Oncology?
Who is the publisher of Molecular Oncology?
